此应用程序的某些内容目前无法使用。
如果这种情况持续存在,请联系我们反馈与联系
1. (AU2016375566) Polymorphic crystalline forms of obeticholic acid

专利局 : 澳大利亚
申请号: 2016375566 申请日: 08.01.2016
公布号: 2016375566 公布日: 29.06.2017
公布类型: A1
专利合作条约参考号: 申请号:US2016012651;公布号: 单击查看数据
国际专利分类:
C07J 9/00
A61K 31/575
A61P 1/16
C07J 17/00
C07J 51/00
C 化学;冶金
07
有机化学
J
甾族化合物
9
含有碳、氢、卤素或氧的正系甾族化合物,在17β位上被1条多于两个碳原子的链所取代,如胆烷、胆甾烷、粪甾烷
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
56
Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
575
substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
A 人类生活必需
61
医学或兽医学;卫生学
P
化合物的治疗活性
1
治疗消化道或消化系统疾病的药物
16
治疗肝脏或胆囊疾病的药物,例如保肝药、利胆药、溶石药
C 化学;冶金
07
有机化学
J
甾族化合物
17
含有碳、氢、卤素或氧的正系甾族化合物,具有1个不与环戊烷并氢化菲骨架稠合的含氧杂环
C 化学;冶金
07
有机化学
J
甾族化合物
51
正系甾族化合物,不属于C07J 1/00至C07J 43/00组的具有未变型环戊烷并氢化菲骨架的
申请人: Intercept Pharmaceuticals, Inc.
发明人:
代理人: Spruson & Ferguson
优先权数据: 14/979,005 22.12.2015 US
标题: (EN) Polymorphic crystalline forms of obeticholic acid
摘要: front page image
(EN) The present application relates to crystalline forms A, D, F, G and I of obeticholic acid. These crystalline forms are useful in the production of Obeticholic acid (in particular its purification), which is a drug useful for the treatment or prevention of a FXR mediated disease or condition, cardiovascular disease or cholestatic liver disease, and for reducing HDL cholesterol, for lowering triglycerides in a mammal, or for inhibition of fibrosis.
也发表为:
CA3009149MYPI 2018000967IL259998SG11201805235XKR1020180095070CN108495858
EP3394081MX2018007776BR112018012590EA201891491PH1/2018/501318ID2019/01700
WO/2017/111979